HCV包膜糖蛋白以环二腺苷酸、STING激动剂或古菌体为佐剂时免疫原性更优
在发现丙型肝炎病毒(HCV)三十年之后,HCV仍是肝移植的主要病因,并构成全球健康重大威胁;尽管直接抗病毒药物取得进展,仍需要预防性疫苗。本研究在小鼠中比较了HCV重组包膜糖蛋白E1E2(rE1E2)与不同佐剂联用时的免疫原性,发现环二腺苷酸(c-di-AMP)和古菌体(archaeosomes)可诱导与氢氧化铝/单磷酰脂质A(Alum/MPLA)及MF59相似的中和抗体,并诱导更强的细胞免疫应答。
要点
- c-di-AMP与古菌体诱导的中和抗体水平与Alum/MPLA及MF59相似
- c-di-AMP与古菌体诱导更强的细胞免疫应答,可检出疫苗特异性多功能CD4+ T细胞
- 作者认为这些佐剂可能大幅提升E1E2疫苗的免疫原性
核心结论
- 作者认为c-di-AMP和古菌体可能大幅提升E1E2疫苗的免疫原性;使用c-di-AMP作佐剂时,部分或完全经鼻免疫方案也可能可行。
研究设计与样本
- 在小鼠中评估HCV rE1E2疫苗与不同佐剂配伍后的免疫原性。
- 重组HCV糖蛋白E1E2(rE1E2)此前与MF59(水包油乳剂型佐剂)联用,已在黑猩猩中显示可降低慢性化率,并在人类志愿者中诱导交叉中和抗体和细胞免疫应答。
主要发现
- c-di-AMP和古菌体诱导的中和抗体与氢氧化铝/单磷酰脂质A(Alum/MPLA)及MF59所诱导的相似。
- c-di-AMP和古菌体均诱导更强的细胞免疫应答,经检出疫苗特异性多功能CD4+ T细胞得到证实。
临床怎么用
- 作者认为这些佐剂可能大幅提升E1E2疫苗的免疫原性。
- 作者的数据还提示,使用c-di-AMP作佐剂时,部分或完全经鼻免疫方案也可能可行。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Three decades after the discovery, hepatitis C virus (HCV) is still the leading cause of liver transplantation and poses a major threat to global health. In spite of recent advances in the development of direct acting antivirals, there is still a need for a prophylactic vaccine to limit the virus spread and protect at-risk populations, especially in developing countries, where the cost of the new treatments may severely limit access. The use of recombinant HCV glycoproteins E1E2 (rE1E2) in combination with the MF59, an oil-in-water emulsion-based adjuvant, has previously been shown to reduce the rate of chronicity in chimpanzees and to induce production of cross-neutralizing antibodies and cellular immune responses in human volunteers. To further improve neutralizing antibody responses in recipients along with robust T cell responses, we have explored the immunogenicity of different adjuvants when formulated with the HCV rE1E2 vaccine in mice. Our data show that cyclic di-adenosine monophosphate (c-di-AMP) and archaeosomes elicit strong neutralizing antibodies similar to those elicited using aluminum hydroxide/monophosphoryl lipid A (Alum/monophos. /MPLA) and MF59. However, both c-di-AMP and archaeosomes induced a more robust cellular immune response, which was confirmed by the detection of vaccine-specific poly-functional CD4+ T cells. We conclude that these adjuvants may substantially boost the immunogenicity of our E1E2 vaccine. In addition, our data also indicates that use of a partial or exclusive intranasal immunization regimen may also be feasible using c-di-AMP as adjuvant.
引用
- Landi A, Law J, Hockman D, et al. Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes. Vaccine. 2017. PMID: 29089195. doi:10.1016/j.vaccine.2017.10.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。